Cabaletta Posts Cell Therapy Data From Third Cohort Of Autoimmune Skin Disorder Trial

Cabaletta Bio Inc CABA has announced 28-day clinical data from the third dose cohort (500 million DSG3-CAART cells) in the DesCAARTes Phase 1 trial for mucosal-dominant pemphigus vulgaris (mPV).
The Company observed a dose-dependent increase in DSG3-CAART persistence in the third cohort relative to the first two low dose cohorts throughout the 28 days following infusion.
In addition, no clinically relevant adverse events (DLTs) were observed.
These safety data were observed without preconditioning and in the presence of circulating anti-DSG3 antibodies.
Dosing of patients in the fourth cohort at a treatment dose of 2.5 billion DSG3-CAART cells has been initiated.
28-day safety data from the fourth dose cohort is expected in the Q1 of 2022.
Top-line biologic activity data for the first two low-dose cohorts will be announced in Q4 of 2021.
Related Link: Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder.
Cabaletta ended Q3 with $119.3 million in cash, extending the cash runway to fund operations through at least 1Q23.
Price Action: CABA shares closed higher by 4.12% at $14.37 on mONDAY.